Weis Cleo-Aron, Yao Xiaopan, Deng Yanhong, Detterbeck Frank C, Marino Mirella, Nicholson Andrew G, Huang James, Ströbel Philipp, Antonicelli Alberto, Marx Alexander
*Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany; †Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut; ‡Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut; §Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy; ║Department of Histopathology, Royal Brompton Hospital, and National Heart and Lung Institute, Imperial College London, London, United Kingdom; ¶Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; and #Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.
J Thorac Oncol. 2015 Feb;10(2):367-72. doi: 10.1097/JTO.0000000000000393.
The rarity of thymomas and lack of multi-institutional studies have hampered therapeutic progress for decades. To overcome this, the members of the International Thymic Malignancy Interest Group created a worldwide retrospective database. This database was analyzed regarding the demographic and geographic distribution of thymomas and the impact of different variables on survival and recurrence.
This study analyzed 4221 thymomas diagnosed between 1983 and 2012 with World Health Organization histotype information from the International Thymic Malignancy Interest Group database. Associations to survival and recurrence were studied by univariate and multivariate analyses.
Type B2 thymoma is the most common (28%) and type A the least common (12%) histotypes. They are significantly more frequent in Europe and the United States than Asia. Type A and AB occur at significantly higher age than other thymomas (64 and 57 years, respectively). There are no differences in gender distribution. Stage is lower in type A (90% in stages I-II) and AB than B1 to B3 thymomas (38% of type B3 in stage III). In univariate analysis, recurrence is significantly less frequent among stage I/II tumors, in type A and AB (recurrence rates, 1-2%) than B1 to B3 thymomas (2-7%). Multivariate analysis reveals an impact of age, stage, and resection status on survival and recurrence, whereas for histology there is only a significant impact on recurrence.
New findings are (1) geographic differences such as a lower incidence of type A and B2 thymoma in Asia; and (2) impact of stage and histology, the latter partially limited to early stage disease, on recurrence.
胸腺瘤较为罕见,且缺乏多机构研究,这几十年来一直阻碍着治疗进展。为克服这一问题,国际胸腺恶性肿瘤兴趣小组的成员创建了一个全球回顾性数据库。该数据库针对胸腺瘤的人口统计学和地理分布以及不同变量对生存和复发的影响进行了分析。
本研究分析了国际胸腺恶性肿瘤兴趣小组数据库中1983年至2012年间诊断的4221例胸腺瘤,这些病例具有世界卫生组织组织学类型信息。通过单因素和多因素分析研究了与生存和复发的关联。
B2型胸腺瘤是最常见的组织学类型(28%),A 型是最不常见的(12%)。它们在欧洲和美国比亚洲更为常见。A 型和 AB 型胸腺瘤的发病年龄明显高于其他胸腺瘤(分别为64岁和57岁)。性别分布没有差异。A 型(I-II期占90%)和 AB 型胸腺瘤的分期低于 B1至B3型胸腺瘤(B3型的III期占38%)。在单因素分析中,I/II期肿瘤、A 型和 AB 型胸腺瘤的复发率(1-2%)明显低于 B1至B3型胸腺瘤(2-7%)。多因素分析显示年龄、分期和切除状态对生存和复发有影响,而对于组织学类型,仅对复发有显著影响。
新发现包括:(1)地理差异,如亚洲 A 型和 B2型胸腺瘤的发病率较低;(2)分期和组织学类型对复发有影响,后者部分局限于早期疾病。